CRMD CorMedix Inc

  1. Stocks
  2. Healthcare
  3. NYSEAMERICAN: CRMD

Price (delayed)

$5.84

Market cap

$321.09M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.91

Enterprise value

$278.04M

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company is focused on developing its ...

Highlights
The company's debt fell by 17% YoY and by 5% QoQ
CorMedix's equity has increased by 27% YoY but it has decreased by 16% QoQ
The gross profit has plunged by 100% from the previous quarter and by 100% YoY
The revenue has plunged by 100% from the previous quarter and by 100% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.cormedix.com
Peers: BDX EBS UTMD

Key stats

What are the main financial stats of CRMD
Market
Shares outstanding
54.98M
Market cap
$321.09M
Enterprise value
$278.04M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.56
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$46.3M
EBITDA
-$46.23M
Free cash flow
-$38.74M
Per share
EPS
-$0.91
Free cash flow per share
-$0.76
Book value per share
$1.28
Revenue per share
$0
TBVPS
$1.61
Balance sheet
Total assets
$82.06M
Total liabilities
$11.92M
Debt
$667,632
Equity
$70.14M
Working capital
$68.05M
Liquidity
Debt to equity
0.01
Current ratio
6.97
Quick ratio
6.68
Net debt/EBITDA
0.93
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-64%
Return on equity
-72.3%
Return on invested capital
-155.4%
Return on capital employed
-65.5%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CRMD stock price

How has the CorMedix stock price performed over time
Intraday
8.75%
1 week
9.98%
1 month
41.4%
1 year
15.87%
YTD
55.32%
QTD
37.74%

Financial performance

How have CorMedix's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$48.96M
Net income
-$46.34M
Gross margin
N/A
Net margin
N/A
The gross profit has plunged by 100% from the previous quarter and by 100% YoY
The revenue has plunged by 100% from the previous quarter and by 100% YoY
The company's operating income has shrunk by 60% YoY and by 17% QoQ
CorMedix's net income has plunged by 56% YoY and by 16% from the previous quarter

Growth

What is CorMedix's growth rate over time

Valuation

What is CorMedix stock price valuation
P/E
N/A
P/B
4.56
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has declined by 23% year-on-year and by 6% since the previous quarter
The P/B is 47% above the last 4 quarters average of 3.1
CorMedix's equity has increased by 27% YoY but it has decreased by 16% QoQ
The revenue has plunged by 100% from the previous quarter and by 100% YoY

Efficiency

How efficient is CorMedix business performance
CorMedix's ROE has decreased by 42% YoY and by 10% from the previous quarter
The ROA has contracted by 38% YoY and by 8% from the previous quarter
The company's return on invested capital rose by 25% YoY but it fell by 2.4% QoQ

Dividends

What is CRMD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CRMD.

Financial health

How did CorMedix financials performed over time
CorMedix's total liabilities has surged by 71% YoY and by 45% QoQ
The quick ratio fell by 41% QoQ and by 28% YoY
The company's debt is 99% lower than its equity
CorMedix's equity has increased by 27% YoY but it has decreased by 16% QoQ
The company's debt fell by 17% YoY and by 5% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.